Mehul Desai Joins Enable Injections as VP, Medical Affairs
We are pleased to announce Mehul Desai, PharmD, MBA, has joined Enable Injections as Vice President of Medical / Clinical Affairs. Desai will lead Enable’s enFuse® medical and clinical programming to support publication, new partnerships, and regulatory approvals.
Desai brings an array of experience in medical and clinical affairs across the pharmaceutical space. He most recently served as Associate Medical Director for argenx, driving the strategic direction, supporting clinical trial execution, and contributing to business development activities across various therapeutic areas. Prior to argenx, his experience includes field medical assignments in rare disease, nephrology and neurology for Mallinckrodt Pharmaceuticals, nephrology and hematology for Alexion Pharmaceuticals, and post-doctoral fellowship work in Medical Affairs for Johnson & Johnson. Desai also served as a clinical instructor of Pharmacy Practice and Pharmacy Administration at the University of the Sciences in Philadelphia.
“I am honored to be joining Enable Injections as the Vice President of Medical / Clinical Affairs and look forward to progressing the breadth and depth of the company’s partnerships, with the goal of getting safe and effective therapies to patients while demonstrating mutual benefit to all stakeholders,” said Dr Desai. “The enFuse® platform has the potential to disrupt the drug delivery space and I am excited to continue the momentum.”
Desai holds a bachelor’s degree in Biochemistry and Business Foundations from Indiana University, Bloomington; a Doctor of Pharmacy from Purdue University; a post-doctoral fellowship with Johnson & Johnson Consumer, Inc.; and a Master of Business Administration in Pharmaceutical and Healthcare Business from the University of the Sciences in Philadelphia.
“We are very excited to welcome Mehul to the Enable team. With his valuable experience in medical and clinical affairs in various roles in the pharma industry, we look forward to the positive impact he will have on our team and collaboration with our pharma partners,” said Mike Hooven, President and CEO, Enable Injections.
To learn more about the enFuse, contact us.